Amarin Corporation plc

Amarin’s revenue base is primarily U.S.-driven, with additional sales in certain European countries and other markets through collaborations with third-party partners. The company maintains a U.S. operating presence (Bridgewater, New Jersey) and a European footprint through subsidiaries in countries including Ireland, Switzerland, Germany, France, the U.K., Italy, Spain, Austria, Belgium, Denmark, Finland, Greece, the Netherlands, Norway, Portugal and Sweden. Outside the U.S., the company’s economics differ by route-to-market: direct sales to wholesalers can carry higher net pricing than partner supply arrangements where partners fund promotion and resale. Geographic expansion and performance depend on country-by-country pricing and reimbursement outcomes, and on partner execution (e.g., the EU Territory licensing arrangement with Recordati). No authoritative percentage revenue-by-region table was provided in the excerpts, so a precise regional split is not disclosed here.

Amarin is substantially dependent on a single product (VASCEPA/VAZKEPA), making results highly sensitive to competitive, pricing and access changes affecting that franchise. In the U.S., generic icosapent ethyl competition and consumer substitution toward non-prescription omega-3 products can pressure both volume and net selling price, and payer/PBM coverage decisions can abruptly reduce demand. The company also faces customer concentration risk because a small number of wholesalers account for a large share of gross product sales and receivables. Outside the U.S., commercialization and pricing/reimbursement outcomes depend heavily on partners, creating execution and counterparty risk (including reliance on Recordati for the EU Territory). Like other pharma companies, Amarin is exposed to regulatory, pharmacovigilance, supply chain, and intellectual property risks that can affect market access and product economics.